What's New
| Continuing Education Risk-adapted Therapy for PV Jerry L. Spivak, MD, MACP |
| Continuing Education The Expanding Role of JAK Inhibitors in MF Ruben Mesa, MD |
| Continuing Education ASH 2020 Meeting Highlights in Myeloproliferative Neoplasms Ruben Mesa, MD; Aaron T. Gerds, MD; and John Mascarenhas, MD |
| FAQ How is red blood cell (RBC) transfusion used to manage anemia in myelofibrosis (MF) patients? Srdan Verstovsek, MD, PhD |
| FAQ How can the mutational profile in myeloproliferative neoplasms (MPN) help to inform diagnosis and prognosis? Aaron T. Gerds, MD, MS |
| FAQ How is risk assessed in PV and how does this risk inform treatment decisions? Jerry L. Spivak, MD, MACP |
| FAQ What are the treatment options for MF-related anemia? Raajit K. Rampal, MD, PhD View all FAQs |